These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20201609)

  • 1. Trends in development of the influenza vaccine with broader cross-protection.
    Stropkovská A; Janulíková J; Varecková E
    Acta Virol; 2010; 54(1):7-19. PubMed ID: 20201609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
    Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
    J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
    Tamura S; Tanimoto T; Kurata T
    Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
    Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
    Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza vaccine immunology.
    Dormitzer PR; Galli G; Castellino F; Golding H; Khurana S; Del Giudice G; Rappuoli R
    Immunol Rev; 2011 Jan; 239(1):167-77. PubMed ID: 21198671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunity against influenza virus infection].
    Takada A
    Nihon Rinsho; 2010 Sep; 68(9):1625-30. PubMed ID: 20845738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pandemic preparedness: toward a universal influenza vaccine.
    Roose K; Fiers W; Saelens X
    Drug News Perspect; 2009 Mar; 22(2):80-92. PubMed ID: 19330167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine design of hemagglutinin glycoprotein against influenza.
    Chen JR; Ma C; Wong CH
    Trends Biotechnol; 2011 Sep; 29(9):426-34. PubMed ID: 21640418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.
    Sabarth N; Howard MK; Savidis-Dacho H; van Maurik A; Barrett PN; Kistner O
    Vaccine; 2010 Jan; 28(3):650-6. PubMed ID: 19896446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
    Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus.
    Rudenko L; Isakova-Sivak I; Donina S
    Vaccine; 2013 Oct; 31(42):4702-5. PubMed ID: 23988294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
    Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A
    Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.